MEDP · NASDAQ · Medical - Diagnostics & Research

Medpace

Runs integrated Phase I–IV trials and laboratory services for drug and device developers.

$600.65
After-hours close+0.17 (+0.03%)
At close$600.48(−1.81%)

Breakdown13F · Form 4

Institutions 139.86%Insiders 2.51%

A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.

Shares outstanding 27.91M · Float 22.50M · 80.6% free float

Top shareholders13F · 13D/G · Form 4

HolderShares% outstandingFormFiled
BlackRock, Inc.2.50M8.95%13FAug 7, 2026
T. Rowe Price Associates, Inc.2.07M7.20%13GAug 14, 2026
Price T Rowe Associates Inc /MD/2.07M7.42%13FAug 14, 2026
AQR Capital Management LLC1.28M4.58%13FAug 14, 2026
Vanguard Portfolio Management LLC1.13M4.06%13FAug 13, 2026

Institutions13F, as of Jun 30, 2026

708 holders · 39.04M shares · 77 new positions · 285 increased · 306 reduced · 109 closed

HolderShares% outstandingChg q/qFiled
BlackRock, Inc.2.50M8.95%+27.8KAug 7, 2026
Price T Rowe Associates Inc /MD/2.07M7.42%+1.78MAug 14, 2026
AQR Capital Management LLC1.28M4.58%−74.9KAug 14, 2026
Vanguard Portfolio Management LLC1.13M4.06%+11.7KAug 13, 2026
Vanguard Capital Management LLC1.03M3.68%+15.7KAug 13, 2026
State Street Corp710.9K2.55%+28.7KAug 7, 2026
Geode Capital Management, LLC710.5K2.55%−34.6KAug 12, 2026
Wasatch Advisors LP636.6K2.28%−137.3KJul 10, 2026

Beneficial owners13D/G · 5% or more, as filed

Holder% of classSharesFormFiled
August J. Troendleincl. Medpace Investors, LLC20.00%5.68M13DDec 1, 2025
T. Rowe Price Associates, Inc.7.20%2.07M13GAug 14, 2026

InsidersForm 4

InsiderRoleShares% outstandingFiled
August J. Troendledirector, 10 percent owner, officer: President & CEO540.5K1.94%Aug 27, 2026
Susan E. Burwigofficer: Exec. VP, Operations63.0K0.23%Jul 29, 2026
Brian T. Carleydirector27.8K0.10%Aug 21, 2026
Stephen P. Ewaldofficer: General Counsel & Corp. Secy.20.3K0.07%Jun 1, 2026
Kevin M. Bradyofficer: CFO & Treasurer16.2K0.06%Aug 24, 2026
Jesse J. Geigerofficer: President15.0K0.05%Mar 19, 2026
Cornelius P. III McCarthydirector12.3K0.04%Aug 13, 2026
Fred B. Jr Davenportdirector3.8K0.01%Aug 21, 2026
Robert O. Kraftdirector9550.00%Aug 28, 2026
Brad W. Hansmanofficer: Exec. VP, Operations6970.00%Jun 4, 2026

2 ten-percent owners hold 27.73M shares by Form 4, outside the officers-and-directors figure above · 4 people have not refiled in the last 18 months (8.3K shares), so they are not in the figure above

Latest trades

DateInsiderTypeSharesAvg priceOwned after
Aug 26, 2026
Robert O. Kraftdirector
Sale3,858$617.81955
Aug 26, 2026
August J. Troendledirector, 10 percent owner, officer: President & CEO
Sale4,000$620.03540,544
Aug 25, 2026
August J. Troendledirector, 10 percent owner, officer: President & CEO
Sale673$620.38544,544
Aug 24, 2026
August J. Troendledirector, 10 percent owner, officer: President & CEO
Sale1,983$620.23545,217
Aug 21, 2026
August J. Troendledirector, 10 percent owner, officer: President & CEO
Sale13,995$624.45547,200
Aug 20, 2026
Kevin M. Bradyofficer: CFO & Treasurer
Sale3,400$625.2412,830
Aug 19, 2026
Brian T. Carleydirector
Sale5,000$608.6327,825
Aug 20, 2026
August J. Troendledirector, 10 percent owner, officer: President & CEO
Sale27,174$618.79561,195
Aug 19, 2026
August J. Troendledirector, 10 percent owner, officer: President & CEO
Sale15,609$606.47588,369
Aug 19, 2026
Fred B. Jr Davenportdirector
Sale7,283$606.153,798

CongressHouse and Senate disclosures

MemberTypeAmountOwnerTradedDisclosed
Rep. David Taylor · OH02Purchase$1,001 – $15,000May 15, 2026May 29, 2026
Rep. David Taylor · OH02Purchase$1,001 – $15,000May 15, 2026May 29, 2026
Rep. David Taylor · OH02Purchase$1,001 – $15,000May 15, 2026May 29, 2026